Acadia Pharma (ACAD) Commences Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder - StreetInsider.com

Submitted by Anonymous (not verified) on Thu, 04/25/2019 - 13:01

Acadia Pharma (ACAD) Commences Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder  StreetInsider.comACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 ...